- Home
- IKT vs LENZ Comparison
IKT vs LENZ Comparison
Compare IKT & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IKT | LENZ |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.1M | 278.4M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IKT | LENZ |
|---|---|---|
| Price | $1.74 | $7.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $5.00 | ★ $44.00 |
| AVG Volume (30 Days) | 722.6K | ★ 857.4K |
| Earning Date | 03-26-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,088,000.00 |
| Revenue This Year | N/A | $50.42 |
| Revenue Next Year | N/A | $197.16 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.33 | $6.61 |
| 52 Week High | $2.26 | $50.19 |
Technical Indicators
Market Signals| Indicator | IKT | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 39.10 |
| Support Level | $1.62 | N/A |
| Resistance Level | $1.74 | $10.42 |
| Average True Range (ATR) | 0.12 | 0.65 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 30.84 | 22.67 |
Price Performance
Historical ComparisonAbout IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.